Want to see SE:VICO full AI Analyst Report?
VICO Stock Chart & Stats
kr10.74
kr0.06(0.53%)
At close: 4:00 PM EDT
kr10.74
kr0.06(0.53%)
Day’s Range― - ―
52-Week Rangekr8.62 - kr18.24
Previous CloseN/A
Volume244.45K
Average Volume (3M)626.49K
Market Cap
kr3.07B
Enterprise Valuekr2.64K
Total Cash (Recent Filing)kr905.64M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Nov 05, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding281,525,600
10 Day Avg. Volume896,293
30 Day Avg. Volume626,485
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.47
Price to Sales (P/S)710.16
P/FCF Ratio-7.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr35.50Price Target Upside230.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.87
Revenue Forecast (FY)kr3.93M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of meaningful debt lowers solvency risk and preserves financial flexibility while Vicore funds clinical development. This gives the company more room to pursue its pipeline without debt-service constraints, although equity funding may still be needed.
Specialized Lung-disease PipelineA focused pipeline in severe lung diseases can concentrate scientific and capital resources around important unmet needs. Continued development of C21 and related programs provides a defined strategic direction and the potential for future milestone or product revenue.
Revenue Growth From A Small BasePositive trailing revenue growth suggests some business activity is progressing despite Vicore remaining development-stage. If this trend persists and scales through partnerships or products, it could gradually diversify funding beyond equity raises, though the current base remains limited.
Bears Say
Very Large Ongoing LossesThe scale of recurring losses indicates that Vicore is not yet economically self-sustaining. Unless clinical assets generate meaningful commercial or partnership income, continued expenses can erode equity and increase reliance on external capital over the coming periods.
Severe Cash BurnDeeply negative operating and free cash flow creates a persistent funding requirement for research and clinical programs. The deterioration in free cash flow suggests burn has not stabilized, raising the risk of future financing, dilution, or reduced development activity.
Limited And Volatile Revenue BaseVery small and volatile revenue provides limited support for the cost base and makes financial performance dependent on pipeline progress, partnerships, or financing. This weak revenue foundation reduces visibility into sustainable cash generation and near-term operating leverage.
Vicore Pharma Holding AB News
VICO FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was kr8.62 and its highest was kr18.24 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is kr3.07B.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Nov 05, 2026 which is in 60 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on Aug 21, 2026. The company reported -kr0.51 earnings per share for the quarter, missing the consensus estimate of -kr0.41 by -kr0.1.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.5.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,525,600 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -kr0.51 in its last earnings report, missing expectations of -kr0.41. Following the earnings report the stock price went down -0.362%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in SE:VICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
VICO Stock 12 Month Forecast
Average Price Target
kr35.50
▲(230.54% Upside)
Technical Analysis
Hansa Biopharma AB
―
Medivir AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Cantargia AB
―